Citalopram versus other antidepressants for depression
by ncbi.nlm.nih.gov
Major depression is a severe mental illness characterised by a persistent and unreactive low mood and loss of all interest and pleasure, usually accompanied by a range of symptoms including appetite change, sleep disturbance, fatigue, loss of energy, poor concentration, psychomotor symptoms, inappropriate guilt and morbid thoughts of death. Antidepressant drugs remain the mainstay of treatment in moderate?to?severe major depression. During the last 20 years, selective serotonin reuptake inhibitors (SSRIs) have progressively become the most commonly prescribed antidepressants. Citalopram, one of the first SSRIs introduced in the market, is the racemic mixture of S? and R?enantiomer. In the present review we assessed the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with all other antidepressants in the acute?phase treatment of major depression. Thirty?seven randomised controlled trials (more than 6000 participants) were included in the present review. In terms of efficacy, citalopram was more efficacious than other reference compounds like paroxetine or reboxetine, but worse than escitalopram. In terms of side effects, citalopram was more acceptable than older antidepressants, like tricyclics. Based on these findings, we conclude that clinicians should focus on practical or clinically relevant considerations including differences in efficacy and side?effect profiles.
Abstract
Background: Recent US and UK clinical practice guidelines recommend that second?generation antidepressants should be considered amongst the best first?line options when drug therapy is indicated for a depressive episode. Systematic reviews have already highlighted some differences in efficacy between second?generation antidepressants. Citalopram, one of the first selective serotonin reuptake inhibitors (SSRI) introduced in the market, is one of these antidepressant drugs that clinicians use for routine depression care.
Objectives: To assess the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with tricyclics, heterocyclics, other SSRIs and other conventional and non?conventional antidepressants in the acute?phase treatment of major depression.
Search methods: We searched The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register and the Cochrane Central Register of Controlled Trials up to February 2012. No language restriction was applied. We contacted pharmaceutical companies and experts in this field for supplemental data.
Selection criteria: Randomised controlled trials allocating patients with major depression to citalopram versus any other antidepressants.
Data collection and analysis: Two reviewers independently extracted data. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy (the number of patients who responded or remitted), patient acceptability (the number of patients who failed to complete the study) and tolerability (side?effects).
Main results: Thirty?seven trials compared citalopram with other antidepressants (such as tricyclics, heterocyclics, SSRIs and other antidepressants, either conventional ones, such as mirtazapine, venlafaxine and reboxetine, or non?conventional, like hypericum). Citalopram was shown to be significantly less effective than escitalopram in achieving acute response (odds ratio (OR) 1.47, 95% confidence interval (CI) 1.08 to 2.02), but more effective than paroxetine (OR 0.65, 95% CI 0.44 to 0.96) and reboxetine (OR 0.63, 95% CI 0.43 to 0.91). Significantly fewer patients allocated to citalopram withdrew from trials due to adverse events compared with patients allocated to tricyclics (OR 0.54, 95% CI 0.38 to 0.78) and fewer patients allocated to citalopram reported at least one side effect than reboxetine or venlafaxine (OR 0.64, 95% CI 0.42 to 0.97 and OR 0.46, 95% CI 0.24 to 0.88, respectively).
Authors' conclusions: Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy, tolerability and acceptability. Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics, reboxetine and venlafaxine, however, it seemed to be less efficacious than escitalopram. As with most systematic reviews in psychopharmacology, the potential for overestimation of treatment effect due to sponsorship bias and publication bias should be borne in mind when interpreting review findings. Economic analyses were not reported in the included studies, however, cost effectiveness information is needed in the field of antidepressant trials.
Source: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0047318/
Friday, May 29, 2026
Arthritis Management and Online Medical Care
Arthritis is a broad term encompassing more than 100 different conditions that cause joint pain, stiffness, and inflammation. The most common forms are osteoarthritis, which results from wear and tear on joint cartilage, and rheumatoid arthritis, an autoimmune condition causing chronic joint inflammation. Together, these conditions affect tens of millions of people worldwide and are a leading cause of disability. Telehealth has become an important tool for managing arthritis and improving patient quality of life. Osteoarthritis most commonly affects the knees, hips, hands, and spine. Symptoms include joint pain that worsens with activity and improves with rest, morning stiffness lasting less than 30 minutes, swelling around joints, and decreased range of motion. Management focuses on pain relief, physical therapy, weight management, and in advanced cases, joint replacement surgery. Telehealth allows patients to have regular check-ins with their physician, discuss medication adjustments, and receive referrals to physical therapy without frequent office visits. Rheumatoid arthritis is a systemic inflammatory condition that affects joints symmetrically, most commonly the small joints of the hands and feet. It causes prolonged morning stiffness, joint swelling, fatigue, and can affect organs including the lungs, heart, and eyes. Treatment with disease-modifying antirheumatic drugs, including biologics, has transformed outcomes for rheumatoid arthritis patients. Regular telehealth monitoring helps track disease activity and medication side effects between rheumatology appointments. Patients who develop infections while on immunosuppressive therapy need prompt antibiotic evaluation, accessible through https://www.amoxilcompharm.com/. Exercise and physical therapy are important components of arthritis management for both osteoarthritis and rheumatoid arthritis. Telehealth platforms can connect patients with physical therapists who deliver virtual exercise instruction, improving joint function and reducing pain. Occupational therapy consultations via telehealth help patients adapt daily activities to accommodate their joint limitations. Pain management for arthritis may include over-the-counter anti-inflammatory medications, prescription medications, topical treatments, injections, and assistive devices. Telehealth providers can help patients navigate the complex options and create individualized treatment plans. For comprehensive arthritis information and telehealth resources, visit https://amoxicillina.online/ for accessible and reliable patient health content.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.